The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted 342 parallel import licences for medicines in 2026, representing a critical regulatory pathway for maintaining pharmaceutical access following Brexit-related supply chain disruptions.
Key takeaways
- MHRA approved 342 parallel import licences in 2026 for medicines sourcing from EU markets
- Parallel imports help address supply shortages and provide cost-effective alternatives to branded medicines
- Post-Brexit regulatory changes have made parallel importation more complex but remain essential for patient access
UK Parallel Import Licensing Activity
Annual licences granted by MHRA, 2024-2026
Source: MHRA, 2026 | Georgian Medical Journal News
Regulatory framework maintains medicine access
Parallel import licences enable pharmaceutical companies to legally import medicines that are already licensed in other European Economic Area countries for sale in the UK market. The MHRA’s regulatory framework ensures these imported medicines meet the same safety and quality standards as directly sourced products.
The 2026 licensing data, published by the UK government, demonstrates continued reliance on this regulatory mechanism despite post-Brexit complexities. Each licence permits importation of specific pharmaceutical products from designated EU member states, providing essential supply chain flexibility.
Post-Brexit pharmaceutical supply dynamics
Brexit fundamentally altered pharmaceutical supply chains between the UK and EU, creating new regulatory barriers and administrative requirements. The European Medicines Agency relocated from London to Amsterdam, necessitating separate UK regulatory pathways for medicine authorisation and importation.
Parallel imports have become increasingly important for addressing medicine shortages and maintaining competitive pricing in the UK market. The World Health Organization recognises parallel importation as a legitimate mechanism for improving medicine access and affordability.
The 342 parallel import licences granted in 2026 represent a 15% increase from 2025, indicating growing dependence on EU-sourced medicines despite Brexit barriers.
— MHRA regulatory data (UK Government Publications, 2026)
Clinical implications for patient care
Healthcare providers rely on parallel imports to ensure consistent medicine availability, particularly for specialty pharmaceuticals and treatments with limited UK manufacturing capacity. The National Institute for Health and Care Excellence has noted that supply disruptions can significantly impact patient outcomes and treatment continuity.
Parallel imported medicines undergo rigorous quality assurance processes, including batch testing and pharmacovigilance monitoring. This regulatory oversight ensures that patient safety standards remain uncompromised regardless of the medicine’s import pathway.
What this means
Frequently asked questions
Are parallel imported medicines as safe as directly sourced ones?
Yes, parallel imported medicines must meet identical safety, quality, and efficacy standards as directly sourced products. MHRA conducts the same rigorous assessment and monitoring processes for all licensed medicines regardless of import pathway.
Why has parallel importation increased since Brexit?
Brexit created new regulatory barriers and supply chain complexities that have made parallel importation more valuable for maintaining medicine access and managing costs. The 15% increase in 2026 licences reflects growing reliance on this regulatory mechanism.
How do parallel imports affect medicine costs?
Parallel imports can reduce medicine costs by introducing competition and alternative supply sources. This is particularly important for maintaining affordable access to specialty pharmaceuticals in the post-Brexit regulatory environment.
The continued growth in parallel import licensing reflects the UK’s pragmatic approach to maintaining pharmaceutical access while navigating post-Brexit regulatory realities. This trend will likely persist as healthcare systems adapt to new supply chain dynamics and regulatory frameworks.
Source: Parallel import licences granted in 2026
Was this article helpful?
Related Coverage
